<List><item><source>MED</source><extId>27932891</extId><pmcid>PMC5135398</pmcid><annotations><annotation><prefix>g with the phase III RAINFALL study (</prefix><exact>NCT02314117</exact><postfix>). </postfix><tags><tag><name>NCT02314117</name><uri>http://identifiers.org/clinicaltrials/NCT02314117</uri></tag></tags><id>http://europepmc.org/articles/PMC5135398#europepmc-8e48745296a15dbac9e750a3c05796bd</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> with chemotherapy (</prefix><exact>NCT02335411</exact><postfix>) and second-line co</postfix><tags><tag><name>NCT02335411</name><uri>http://identifiers.org/clinicaltrials/NCT02335411</uri></tag></tags><id>http://europepmc.org/articles/PMC5135398#europepmc-c297fbefa3f0da1717d3825bbbe88d8f</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ond-line comparison with paclitaxel (</prefix><exact>NCT02370498</exact><postfix>). </postfix><tags><tag><name>NCT02370498</name><uri>http://identifiers.org/clinicaltrials/NCT02370498</uri></tag></tags><id>http://europepmc.org/articles/PMC5135398#europepmc-8d9e8414358d02121a7d4b16d982607a</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>I INNOVATION trial (</prefix><exact>NCT02205047</exact><postfix>) opened in 2015, co</postfix><tags><tag><name>NCT02205047</name><uri>http://identifiers.org/clinicaltrials/NCT02205047</uri></tag></tags><id>http://europepmc.org/articles/PMC5135398#europepmc-1e6c97e59aa31677819f73d9b8cee559</id><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>with pembrolizumab (</prefix><exact>NCT02318901</exact><postfix>) and margetuximab (</postfix><tags><tag><name>NCT02318901</name><uri>http://identifiers.org/clinicaltrials/NCT02318901</uri></tag></tags><id>http://europepmc.org/articles/PMC5135398#europepmc-1c3760d0a88ec56b47840f866fd0178b</id><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> with pembrolizumab (</prefix><exact>NCT02689284</exact><postfix>), respectively.54 </postfix><tags><tag><name>NCT02689284</name><uri>http://identifiers.org/clinicaltrials/NCT02689284</uri></tag></tags><id>http://europepmc.org/articles/PMC5135398#europepmc-23d3c021d78cade90025b7e6109e66e7</id><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>